Rallybio(US:RLYB)2025-11-06 13:12Financial Performance - Rallybio generated $20 million from the sale of its interest in REV102, including $7.5 million upfront and $12.5 million for additional preclinical studies[4] - Revenue for Q3 2025 was $0.2 million, a decrease from $0.3 million in Q3 2024, primarily due to the collaboration agreement with Johnson & Johnson[10] - Rallybio reported a net income of $16.0 million, or $0.36 per common share, compared to a net loss of $11.5 million, or $0.26 per common share, in Q3 2024[10] - Total operating expenses for Q3 2025 were $7.1 million, down from $12.4 million in Q3 2024[10] Research and Development - R&D expenses decreased to $4.1 million in Q3 2025 from $8.2 million in Q3 2024, attributed to reduced development costs and workforce reduction[10] - RLYB116's Phase 1 confirmatory PK/PD study completed dosing in Cohort 1, with data expected in Q4 2025[5] - RLYB332 is being evaluated for future development as a potential best-in-class treatment for diseases of iron overload[6] General and Administrative Expenses - G&A expenses were $3.0 million in Q3 2025, down from $4.1 million in Q3 2024, mainly due to lower headcount[10] Financial Position - Cash, cash equivalents, and marketable securities totaled $59.3 million as of September 30, 2025, sufficient to support operations through 2027[10] - Rallybio's total stockholders' equity increased to $63.0 million as of September 30, 2025, from $61.7 million at the end of 2024[14]